[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6213 Introduced in House (IH)]
<DOC>
116th CONGRESS
2d Session
H. R. 6213
To provide for coverage (without cost sharing or utilization management
requirements) under group health plans and individual and group health
insurance coverage of testing for COVID-19.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
March 11, 2020
Ms. Wilson of Florida (for herself, Ms. Schrier, Ms. DelBene, Ms.
DeGette, Mr. Grijalva, Mr. Courtney, Mr. Sablan, Ms. Bonamici, Mr.
DeSaulnier, Ms. Jayapal, Mr. Morelle, Mrs. McBath, Mrs. Hayes, Ms.
Shalala, Mr. Levin of Michigan, Mr. Trone, Ms. Stevens, and Mr. Scott
of Virginia) introduced the following bill; which was referred to the
Committee on Energy and Commerce, and in addition to the Committees on
Ways and Means, and Education and Labor, for a period to be
subsequently determined by the Speaker, in each case for consideration
of such provisions as fall within the jurisdiction of the committee
concerned
_______________________________________________________________________
A BILL
To provide for coverage (without cost sharing or utilization management
requirements) under group health plans and individual and group health
insurance coverage of testing for COVID-19.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``No Cost for COVID-19 Testing Act''.
SEC. 2. COVERAGE OF TESTING FOR COVID-19.
(a) In General.--A group health plan and a health insurance issuer
offering group or individual health insurance coverage (including a
grandfathered health plan (as defined in section 1251(e) of the Patient
Protection and Affordable Care Act)) shall provide coverage, and shall
not impose any cost sharing (including deductibles, copayments, and
coinsurance) requirements or prior authorization or other utilization
management requirements, for at a minimum the following items and
services furnished during any portion of the emergency period defined
in paragraph (1)(B) of section 1135(g) of the Social Security Act (42
U.S.C. 1320b-5(g)) beginning on or after the date of the enactment of
this Act:
(1) In vitro diagnostic products (as defined in section
809.3(a) of title 21, Code of Federal Regulations) for the
detection of SARS-CoV-2 or the diagnosis of the virus that
causes COVID-19 that are approved, cleared, or authorized under
section 510(k), 513, 515 or 564 of the Federal Food, Drug, and
Cosmetic Act, and the administration of such in vitro
diagnostic products.
(2) Health care provider office visits, urgent care center
visits, and emergency room visits relating to testing for
COVID-19.
(b) Enforcement.--The provisions of subsection (a) shall be applied
by the Secretary of Health and Human Services, Secretary of Labor, and
Secretary of the Treasury to group health plans and health insurance
issuers offering group or individual health insurance coverage as if
included in the provisions of part A of title XXVII of the Public
Health Service Act, part 7 of the Employee Retirement Income Security
Act of 1974, and subchapter B of chapter 100 of the Internal Revenue
Code of 1986, as applicable.
(c) Implementation.--The Secretary of Health and Human Services,
Secretary of Labor, and Secretary of the Treasury may implement the
provisions of this section through program instruction or otherwise.
(d) Health Insurance Terms.--The terms ``group health plan'';
``health insurance issuer''; ``group health insurance coverage'', and
``individual health insurance coverage'' have the meanings given such
terms in section 2791 of the Public Health Service Act (42 U.S.C.
300gg-91), section 733 of the Employee Retirement Income Security Act
of 1974 (29 U.S.C. 1191b), and section 9832 of the Internal Revenue
Code of 1986, as applicable.
<all>